MUMBAI, India, Oct. 12 -- Intellectual Property India has published a patent application (202641119570 A) filed by Dr. N. Kayalvizhi; and Dr. C. Gurumoorthy on October 06, 2026, for Start-Up Process Operation Of The Two Stage Anaerobic Bioreactor For Treating Pharmaceutical Wastewater.
Inventors include Dr. N. Kayalvizhi; and Dr. C. Gurumoorthy.
The application for the patent was published on October 09, 2026, under issue no. 41/2026.
Abstract: Abstract The present invention relates to a start-up process operation of a two-stage anaerobic bioreactor for treating pharmaceutical wastewater, particularly to a controlled method for establishing microbial activity, acclimatization and stable anaerobic treatment during initiation of reactor operation. The process comprises introducing an anaerobic microbial inoculum into first-stage and second-stage anaerobic reactors and gradually introducing pharmaceutical wastewater under controlled operating conditions. The first-stage reactor primarily facilitates hydrolysis and acidogenesis of complex organic matter, while the second-stage reactor facilitates acetogenesis and methanogenesis of intermediate organic compounds, resulting in organic matter degradation and biogas generation. During start-up, the organic loading rate and wastewater strength are progressively increased based on monitored process parameters including chemical oxygen demand, pH, alkalinity, volatile fatty acids, hydraulic retention time, biogas production, methane content and effluent quality. Controlled inter-stage transfer is employed to regulate the loading of the second-stage reactor and reduce excessive accumulation of acidic intermediates. The process further provides sequential inoculation, low-loading, acclimatization, loading-stabilization and stable-operation phases. The controlled start-up strategy promotes microbial adaptation, process stability, organic pollutant degradation, methane-rich biogas generation and improved treatment performance while reducing the risk of acidification and microbial inhibition associated with pharmaceutical wastewater.
Disclaimer: Curated by HT Syndication.
